Aponvie (aprepitant) — Medical Benefit Pharmaceutical Policy
Customize your policy alerts
Sign up for Geisinger Health Plan Policy MBP 299.0 alerts
Get alerted when Policy MBP 299.0 changes without checking for updates manually.
Monitor payer policy activity
This medical benefit pharmaceutical policy governs prior authorization and coverage criteria for Aponvie (aprepitant) for prevention of postoperative nausea and vomiting (PONV) for Geisinger Health Plan members across applicable commercial, Medicare, and CHIP lines of business.
No material clinical or coverage changes in this revision.
Coverage Criteria for Aponvie (aprepitant)
Initial authorization criteria
Aponvie (aprepitant) will be considered medically necessary when ALL of the following are met:
Eligibility and contract-specific benefit limitations and exclusions apply to coverage of Aponvie (aprepitant). Line of business benefit documents (for example, Commercial, Medicare, or CHIP plan benefit booklets) take precedence and will supersede the statements in this policy when there is a conflict.
Provider Requirements and Action Items
Prior authorization required
Prior authorization is required and must be obtained from the Medical Director or their designee. Approved requests will be authorized one time for one administration of Aponvie.
No step therapy requirements
There are no step therapy requirements for Aponvie specified in this policy.
Required medical record documentation
Document in the medical record that the member is at least 18 years old, that the medication is being used for prevention of postoperative nausea and vomiting (PONV), and that the prescriber is a surgeon or anesthesiologist.
- Age: medical record evidence member is 18 years of age or older
- Indication: documentation the use is for prevention of post-operative nausea and vomiting (PONV)
- Prescriber: documentation that the medication is prescribed by a surgeon or anesthesiologist
Denial triggers
The request may be denied if the medical record does not document the member is ≥18 years old, the indication is not prevention of PONV, or the prescriber is not a surgeon or anesthesiologist.
- Member age < 18 years documented or not documented
- Indication other than prevention of postoperative nausea and vomiting or indication not documented
- Prescriber not a surgeon or anesthesiologist or prescriber role not documented
Initial Therapy
Initial therapy — Authorization for initial use
Authorization for initial use
One-time authorization for one administration
Quantity and Dosing Limits
Site of Care Considerations
One administration; perioperative/surgical setting implied
Policy authorizes a single administration (one vial) and refers to perioperative use; while a specific site is not mandated, the setting implied is a perioperative/surgical (hospital outpatient) context.
- Authorization is for one administration (one vial, 32 mg/4.4 mL)
- Site of care is not mandated but implies perioperative/surgical (hospital outpatient) setting
Definitions
Background
Aponvie (aprepitant) is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors used to inhibit emesis; it crosses the blood‑brain barrier to occupy brain NK1 receptors. The agent is indicated in this policy for the prevention of postoperative nausea and vomiting (PONV).
For use under this policy, prior authorization is required and approvals are limited to a one‑time authorization for one administration. Documentation must confirm the member is 18 years of age or older, that the medication is prescribed for prevention of PONV, and that the prescriber is a surgeon or anesthesiologist. Quantity is limited to one vial (32 mg/4.4 mL) per day.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.